Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Urologe A ; 57(3): 295-299, 2018 Mar.
Article in German | MEDLINE | ID: mdl-29487949

ABSTRACT

The incidence of small renal masses ≤4 cm is increasing due to the widespread use of cross-sectional imaging. The majority of these represent indolent forms, but the risk for developing metastases is reported in up to 6% of patients. Particularly in old and comorbid patients surgery might be harmful overtreatment. Thus, there is an increasing demand to establish oncologically safe active surveillance protocols. Radiographic or biopsy-based biological markers to appropriately designate candidates for active surveillance are currently the focus of research.


Subject(s)
Kidney Neoplasms/pathology , Watchful Waiting , Biopsy , Comorbidity , Germany/epidemiology , Humans , Incidence , Kidney Neoplasms/epidemiology
2.
Urologe A ; 57(3): 280-284, 2018 Mar.
Article in German | MEDLINE | ID: mdl-29468282

ABSTRACT

BACKGROUND: Several new treatment strategies have emerged in the treatment of small renal masses (<4 cm in diameter). Active surveillance and ablative techniques have been introduced but it remains unclear which patients will benefit the most from these new treatment options. A surgical approach remains standard of care. In recent decades, radical nephrectomy has been replaced by nephron-sparing surgery for the management of small renal masses. RESULTS: In addition to the open partial nephrectomy, which is considered the standard approach, the number of surgeries performed using minimally invasive techniques is increasing. Recent data show that there might be some benefits such as less blood loss. The disadvantages shown by laparoscopic partial nephrectomy such as prolonged warm ischemia, longer operation times, and postoperative renal impairment might be negligible for the robotic approach. Therefore, current guidelines allow these approaches in addition to open partial nephrectomy if sufficient surgical expertise is given.


Subject(s)
Carcinoma, Renal Cell/surgery , Kidney Neoplasms/surgery , Minimally Invasive Surgical Procedures/methods , Nephrectomy/methods , Robotics , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/pathology , Humans , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/pathology , Laparoscopy , Nephrons
3.
Urolithiasis ; 46(6): 587-593, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29356873

ABSTRACT

The purpose of this study is to analyze clinical outcomes and costs of single-use flexible ureterorenoscopes in comparison with reusable flexible ureterorenoscopes in a tertiary referral center. Prospectively, 68 flexible ureterorenoscopies utilizing reusable (Flex-X2S, Flex-XC, Karl Storz) and 68 applying single-use flexible ureterorenoscopes (LithoVue, Boston Scientific) were collected. Clinical outcome parameters such as overall success rate, complication rates according to Clavien-Dindo, operation time and radiation exposure time were measured. Cost analysis was based on purchase costs and recurrent costs for repair and reprocessing divided by number of procedures. In each group 68 procedures were available for evaluation. In 91% of reusable and 88% of single-use ureterorenoscopies stone disease was treated with a mean stone burden of 101 ± 226 and 90 ± 244 mm2 and lower pole involvement in 47 and 41%, respectively (p > 0.05). Comparing clinical outcomes of reusable vs. single-use instruments revealed no significant difference for overall success rates (81 vs. 87%), stone-free rates (82 vs. 85%), operation time (76.2 ± 46.8 vs. 76.8 ± 40.2 min), radiation exposure time (3.83 ± 3.15 vs. 3.93 ± 4.43 min) and complication rates (7 vs. 17%) (p > 0.05). A wide range of repair and purchase costs resulted in total to $1212-$1743 per procedure for reusable ureterorenoscopy whereas price of single-use ureterorenoscopy was $1300-$3180 per procedure. The current work provided evidence for equal clinical effectiveness of reusable and single-use flexible ureterorenoscopes. Partially overlapping ranges of costs for single-use and reusable scopes stress the importance to precisely know the expenses and caseload when negotiating purchase prices, repair prices and warranty conditions.


Subject(s)
Cost-Benefit Analysis , Postoperative Complications/epidemiology , Ureteroscopes/adverse effects , Ureteroscopy/instrumentation , Urinary Calculi/surgery , Adult , Aged , Disposable Equipment/economics , Equipment Failure/economics , Equipment Failure/statistics & numerical data , Equipment Reuse/economics , Female , Humans , Male , Middle Aged , Operative Time , Postoperative Complications/etiology , Prospective Studies , Treatment Outcome , Ureteroscopes/economics , Ureteroscopy/economics
4.
Oncogene ; 36(28): 3964-3975, 2017 07 13.
Article in English | MEDLINE | ID: mdl-28288135

ABSTRACT

The acquisition of an invasive phenotype by epithelial cells occurs through a loss of cellular adhesion and polarity, heralding a multistep process that leads to metastatic dissemination. Since its characterization in 1995, epithelial-mesenchymal transition (EMT) has been closely linked to the metastatic process. As a defining aspect of EMT, loss of cell adhesion through downregulation of E-cadherin is carried out by several transcriptional repressors; key among them the SNAI family of transcription factors. Here we identify for the first time that Lyn kinase functions as a key modulator of SNAI family protein localization and stability through control of the Vav-Rac1-PAK1 (Vav-Rac1-p21-activated kinase) pathway. Accordingly, targeting Lyn in vitro reduces EMT and in vivo reduces metastasis of primary tumors. We also demonstrate the clinical relevance of targeting Lyn as a key player controlling EMT; patient samples across many cancers revealed a strong negative correlation between Lyn and E-cadherin, and high Lyn expression in metastatic tumors as well as metastasis-prone primary tumors. This work reveals a novel pancancer mechanism of Lyn-dependent control of EMT and further underscores the role of this kinase in tumor progression.


Subject(s)
Neoplasm Metastasis/prevention & control , RNA, Small Interfering/pharmacology , Snail Family Transcription Factors/metabolism , src-Family Kinases/genetics , Animals , Cell Line, Tumor , Epithelial-Mesenchymal Transition/drug effects , Epithelial-Mesenchymal Transition/genetics , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Molecular Targeted Therapy , Neoplasm Metastasis/genetics , Neoplasms/genetics , Neoplasms/pathology , Protein Transport/drug effects , Protein Transport/genetics , Xenograft Model Antitumor Assays , src-Family Kinases/antagonists & inhibitors
5.
World J Urol ; 35(6): 913-919, 2017 Jun.
Article in English | MEDLINE | ID: mdl-27734132

ABSTRACT

PURPOSE: To evaluate stool habits and associated quality of life (QoL) in a matched pair analysis of patients who underwent continent cutaneous diversion using the ileocecal segment [Mainz pouch I (MzPI)] with an intussuscepted ileal nipple as efferent segment with those receiving an ileal conduit (IC) after radical cystectomy. METHODS: We identified 250 patients who underwent radical cystectomy and urinary diversion (UD) with either MzPI with an ileal nipple or IC in our database. A detailed history of stool habits using the modified Wexner score was obtained, and questions addressing general lifestyle, comparison of symptom differences before and after surgery considering bowel function as well as bowel-associated QoL were assessed. RESULTS: Forty-five age- and sex-matched pairs could be compared. Overall, stool incontinence (p = 0.481) and the Wexner score (p = 0.464) revealed no differences between both groups. However, patients with MzPI as compared to those with IC had significant higher rates of stool frequency (53 vs 31 %), softer stool consistencies (60 vs 13 %), diarrhea (62 vs 20 %) and a lower rate of constipation (4 vs 22 %). Patients with MzPI had a trend toward lower bowel-associated QoL compared with patients with IC. Similarly, the MzPI group reported a significantly impaired overall postoperative QoL (51 %) compared to the IC group (29 %) (p = 0.024). CONCLUSIONS: Patients following UD by MzPI have an increased stool frequency and softer stool consistency. However, there is no difference between both groups in terms of de novo stool incontinence. Change in bowel habits should be part of preoperative informed consent in any kind of UD. Careful patient selection is of paramount importance.


Subject(s)
Quality of Life , Urinary Bladder Neoplasms/surgery , Urinary Diversion/methods , Urinary Diversion/psychology , Urinary Reservoirs, Continent , Adult , Aged , Case-Control Studies , Constipation/epidemiology , Constipation/physiopathology , Cystectomy/adverse effects , Cystectomy/methods , Fecal Incontinence/epidemiology , Fecal Incontinence/physiopathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Risk Assessment , Surveys and Questionnaires , Treatment Outcome , Urinary Bladder Neoplasms/pathology
6.
J Pediatr Urol ; 12(6): 404.e1-404.e6, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27570092

ABSTRACT

INTRODUCTION: Rhabdomyosarcoma (RMS) accounts for 5% of all pediatric tumors; 15-20% of these tumors are located in the urogenital tract, mostly originating from the prostate or bladder. In the light of the steadily improving prognosis for patients with RMS through interdisciplinary-multimodal study protocols with 60-70% long-term survivors, non oncological aspects such as erectile function (EF) have become increasingly important. The aim of this study was to evaluate EF in patients having undergone treatment for RMS of the bladder and prostate. DESIGN: The medical records of 24 male patients having undergone surgical treatment for pelvic RMS between 1975 and 2014 were reviewed, and follow-up was obtained. Erectile function was determined using the Self-Estimation Index of Erectile Function-No Sexual Intercourse (SIEF-NS) and the Erection Hardness Scale (EHS). Potential prognostic factors were evaluated in respect to their impact on EF. RESULTS: Thirteen patients were included in the study (median age 20 years). Median follow-up period was 12.7 years (1.09-39.85). All patients completed the EHS; nine patients completed the SIEF-NS. All three patients with preserved erectile function (EHS = 4) showed a score indicating no or minimal impairment on sexual function on SIEF-NS (median 33). None of these patients had undergone external radiotherapy, and radical cystoprostatectomy had been performed before the third year of life in two out of three. The remaining patients had erectile dysfunction (EHS = 0). Three patients had an unsatisfying treatment attempt with sildenafil. Seven patients, including all with failures of oral PDE-5-inhibitors, were successfully treated with intracavernous injection of Alprostadil (Summary Table). DISCUSSION: This was the largest study, to date, evaluating erectile EF in patients treated for RMS of the bladder or prostate. EF was preserved in some patients, despite aggressive treatment modalities. Patients affected by erectile dysfunction after therapy showed limited response to PDE-5 inhibitors, but even after failure of the latter, an intracavernous injection of Alprostadil showed a significant improvement in EHS and SIEF-NS. Limitations of the study included the retrospective nature, small sample size, and heterogeneity of underlying disease, stage, and treatment modalities used. CONCLUSIONS: The results suggested that in a subset of patients, EF was preserved after radical surgical treatment of RMS, especially in young boys. Intracavernous injection of Alprostadil was effective, even after failure of PDE-5-inhibitors, and should be offered to patients without spontaneous erections, whereas PDE-5-inhibitors appeared to be largely ineffective. External radiation therapy appeared to have a negative impact on EF.


Subject(s)
Penile Erection , Postoperative Complications/epidemiology , Prostatic Neoplasms/surgery , Rhabdomyosarcoma/surgery , Urinary Bladder Neoplasms/surgery , Adolescent , Adult , Child , Child, Preschool , Erectile Dysfunction/etiology , Follow-Up Studies , Humans , Infant , Male , Postoperative Complications/etiology , Prostatic Neoplasms/physiopathology , Retrospective Studies , Rhabdomyosarcoma/physiopathology , Urinary Bladder Neoplasms/physiopathology , Young Adult
7.
World J Urol ; 34(2): 275-80, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26070659

ABSTRACT

PURPOSE: Pubic symphysitis (PS) after urological operations is uncommon. This is a systematic single-institution review of patients with transurethral resection of the prostate (TUR-P) with the aim to determine the incidence of PS after TUR-P and to identify a risk profile. MATERIALS AND METHODS: In the past 15 years, 12,118 transurethral operations were performed in our department, 33.4% (n = 4045) were TUR-P, and 84.6% (n = 3421) had routine suprapubic trocar placement. A systematic retrospective analysis identified 12 patients, who developed PS (0.297%). RESULTS: Median age was 69.5 years (64-83). All patients had voiding difficulties. Urine culture had been positive in three cases. All 12 TUR-Ps were monopolar resections, and n = 11 patients had a suprapubic trocar. Median resection weight was 47.5 g (10-100). Two patients had a perforation of the capsule. Histopathological examination revealed chronic prostatitis in nine cases. After 1.0 ± 1.2 months, all patients developed pain in the pubic region. All patients underwent MRI, which suggested PS. Symptomatic and antibiotic medications were administered. Final outcome was resolution of symptoms in all patients after 3.8 ± 5.6 months. No patient retained voiding difficulties. CONCLUSION: PS remains a rare complication after TUR-P. We could not identify a single cause for developing PS. In our study, suprapubic trocar placement (11/12), chronic prostatic inflammation (9/12), previous UTI (3/12) and extended resection (2/12) were overrepresented. Inflammatory, thermic and/or surgical damage of the capsule may be causative. Patients require antibiotic and symptomatic medication. However, prognosis for remission is excellent.


Subject(s)
Osteitis/epidemiology , Postoperative Complications , Prostatic Diseases/surgery , Pubic Bone , Transurethral Resection of Prostate/adverse effects , Aged , Aged, 80 and over , Germany/epidemiology , Humans , Incidence , Magnetic Resonance Imaging , Male , Middle Aged , Osteitis/diagnosis , Osteitis/etiology , Retrospective Studies
8.
Urologe A ; 51(4): 507-9, 512-4, 2012 Apr.
Article in German | MEDLINE | ID: mdl-22402977

ABSTRACT

Metabolic long-term complications and consequences after urinary diversion are somewhat neglected. Subclinical metabolic disturbances are quite common; however, complications are rare. The absorptive surface of the bowel segment is lost for the physiological function of the gastrointestinal tract. Some studies demonstrated that at least some of the absorbent and secreting properties of the bowel are preserved if exposed to urine. For each bowel segment typical complications are reported. Using ileal and/or colon segments, hyperchloremic metabolic acidosis may occur. Studies demonstrated that metabolic effects are not as severe as suspected and could be prevented if a prophylactic treatment is started early.The resection of ileal segments is responsible for malabsorption of vitamin B(12) and bile acid; when using colonic segments, electrolyte disturbances are more common. Careful patient selection, meticulous follow-up and prophylactic treatment are crucial to prevent metabolic complications.


Subject(s)
Malabsorption Syndromes/diagnosis , Malabsorption Syndromes/etiology , Urinary Diversion/adverse effects , Diagnosis, Differential , Humans , Malabsorption Syndromes/prevention & control
9.
Urologe A ; 51(3): 352-6, 2012 Mar.
Article in German | MEDLINE | ID: mdl-22350015

ABSTRACT

Therapy of vesicoureteral reflux (VUR) has steadily changed during the last decade. Open surgical procedures, e.g. extravesical reflux repair with the Lich-Gregoir technique or ureterocystoneostomy with the psoas hitch technique, reference standards with excellent success rates, are less frequently used. Since its approval by the US Food and Drug Administration (FDA) endoscopic reflux therapy with Deflux® has gained more and more popularity. However, the usage of so-called bulking agents, e.g. Deflux®, still remains controversial in dilating reflux, while its application for low-grade VUR is increasingly being accepted. Despite higher recurrence rates in all grades of VUR, the use of the "minimally invasive injection" is increasing. The question has to be answered which therapy - if necessary - benefits the patient most. Which role has the subureteral injection gained and are open surgical procedures for VUR therapy "out"?


Subject(s)
Cystoscopy/methods , Laparoscopy/methods , Ureteroscopy/methods , Vesico-Ureteral Reflux/surgery , Child , Child, Preschool , Dextrans/administration & dosage , Female , Follow-Up Studies , Humans , Hyaluronic Acid/administration & dosage , Infant , Male , Prostheses and Implants , Randomized Controlled Trials as Topic , Recurrence , Urodynamics/physiology , Vesico-Ureteral Reflux/physiopathology
10.
Nature ; 364(6433): 149-51, 1993 Jul 08.
Article in English | MEDLINE | ID: mdl-7686631

ABSTRACT

Neutrophil recruitment into tissues is a multistep process involving sequential engagement of adhesion molecules, including selectins (E,P,L), which are reactive with oligosaccharides, and the family of beta 2 integrins which are reactive with endothelial intercellular adhesion molecules. These processes result in the initial rolling of leukocytes along the endothelial surfaces, followed by the firm attachment of leukocytes to the endothelium. The intravenous infusion of cobra venom factor into rats results in acute lung injury that is neutrophil-dependent, oxygen radical mediated and P-selectin-dependent. Here we report that infusion of sialyl-Lewis X, a ligand for P-selectin, dramatically reduced lung injury and diminished the tissue accumulation of neutrophils, whereas irrelevant oligosaccharides had no such effects. These results suggest that sialyl-Lewis X carbohydrates may be used as a new strategy for anti-inflammatory therapy.


Subject(s)
Cell Adhesion Molecules/physiology , Lewis X Antigen/pharmacology , Lung Diseases/prevention & control , Neutrophils/physiology , Platelet Membrane Glycoproteins/physiology , Animals , Carbohydrate Sequence , Cell Movement/drug effects , Cell Movement/physiology , Dose-Response Relationship, Drug , Elapid Venoms/antagonists & inhibitors , Lung Diseases/chemically induced , Lung Diseases/immunology , Molecular Sequence Data , Neutrophils/drug effects , P-Selectin , Platelet Membrane Glycoproteins/antagonists & inhibitors , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...